BioCryst Pharmaceuticals Inc.

01/07/2022 | Press release | Distributed by Public on 01/07/2022 08:29

BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH